Lille Model Calculator for Alcoholic Hepatitis- Free Steroid Response and 6-Month Mortality Prediction Tool

About This Lille Model Calculator

This Lille Model calculator is designed for healthcare professionals managing patients with severe alcohol-associated hepatitis who are receiving corticosteroid therapy. The tool accepts six clinical inputs (age, serum albumin, total bilirubin at day 0 and day 7, serum creatinine, and prothrombin time) and computes the Lille score using the validated logistic regression formula published by Louvet and colleagues in Hepatology (2007). It supports both SI units (g/L, umol/L) and conventional units (g/dL, mg/dL) with automatic conversion, making it accessible to clinicians worldwide regardless of their laboratory’s reporting standards.

The calculator applies the original Lille Model formula with the logistic transformation to produce a score between 0 and 1, then classifies patients using both the traditional binary cutoff of 0.45 (steroid responder versus non-responder) and the refined three-tier Louvet classification from 2015 (complete responder below 0.16, partial responder 0.16-0.56, null responder above 0.56). The binary renal insufficiency variable is automatically determined from the entered creatinine value using the 1.3 mg/dL (115 umol/L) threshold established in the original study.

Results are displayed on an interactive horizontal zone bar showing the score position across risk classification zones, alongside a clinical decision tree that highlights the appropriate treatment pathway for each tier. The calculation details tab provides a complete breakdown of each variable contribution to the linear predictor R value, supporting transparency and educational understanding of the formula. All clinical recommendations are based on evidence from the AASLD, EASL, and ACG guidelines for the management of severe alcoholic hepatitis.

Lille Model Calculator for Alcoholic Hepatitis: Complete Guide to Steroid Response Assessment and 6-Month Mortality Prediction

Alcohol-associated hepatitis (AH), historically referred to as alcoholic hepatitis, is a severe inflammatory liver condition caused by excessive alcohol consumption. In its most acute form, severe AH carries a short-term mortality rate of 20 to 40 percent, making it one of the most dangerous presentations of liver disease. Corticosteroids, particularly prednisolone, remain the primary pharmacological treatment for severe AH, but not all patients respond favorably to this therapy. Identifying steroid non-responders early is critical because continuing corticosteroids in patients who do not benefit exposes them to unnecessary risks, including infection, while delaying consideration of alternative treatments such as liver transplantation. The Lille Model was developed precisely for this purpose: to evaluate whether a patient with severe AH is responding to corticosteroid therapy after 7 days of treatment, and to predict 6-month mortality based on that response.

Developed by Louvet and colleagues at the Centre Hospitalier Regional Universitaire (CHRU) de Lille in France and published in Hepatology in 2007, the Lille Model integrates six clinical variables, five measured at baseline (day 0) and one measured after 7 days of corticosteroid treatment, into a single prognostic score. The model was derived from a cohort of 320 patients with biopsy-proven severe AH and validated in an independent cohort of 118 patients. The Lille score ranges from 0 to 1, with a critical threshold of 0.45: scores below this cutoff are associated with approximately 85 percent 6-month survival, while scores at or above 0.45 correlate with only about 25 percent 6-month survival. This stark difference in outcomes makes the Lille Model an essential tool in clinical hepatology practice worldwide.

Understanding Severe Alcohol-Associated Hepatitis

Alcohol-associated hepatitis represents an acute inflammatory injury to the liver caused by heavy and prolonged alcohol consumption. While many individuals who drink excessively may develop fatty liver (steatosis) without significant symptoms, a subset progresses to hepatitis characterized by hepatocyte injury, neutrophilic infiltration, Mallory-Denk bodies, and varying degrees of fibrosis or cirrhosis. The severe form, typically defined by a Maddrey Discriminant Function (MDF) score greater than 32 or a Model for End-Stage Liver Disease (MELD) score of 20 or higher, carries substantial short-term mortality. Patients often present with jaundice, ascites, hepatic encephalopathy, and coagulopathy, reflecting profound hepatic dysfunction.

The pathophysiology involves a complex interplay of oxidative stress from alcohol metabolism, gut-derived endotoxemia, activation of innate immune pathways including Kupffer cells and toll-like receptors, and subsequent release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukins. This inflammatory cascade leads to hepatocyte necrosis and apoptosis, perpetuating liver injury. The severity of the inflammatory response and the degree of underlying fibrosis largely determine the clinical outcome. In patients with severe AH, the liver’s synthetic capacity is markedly impaired, reflected by low albumin levels, prolonged prothrombin time, and elevated bilirubin, which are precisely the variables incorporated into the Lille Model.

Clinical Context: Why Steroid Response Assessment Matters

Corticosteroids, specifically prednisolone at a dose of 40 mg daily for 28 days, have been the standard of care for severe AH for decades. The rationale for corticosteroid use rests on their ability to suppress the exaggerated inflammatory response driving hepatocyte injury. Multiple randomized controlled trials and meta-analyses have demonstrated a modest survival benefit with corticosteroid therapy in severe AH, particularly in the short term. However, approximately 40 percent of patients treated with steroids do not respond, and these non-responders have a significantly worse prognosis than responders.

Before the Lille Model was introduced, clinicians had limited tools to identify non-responders early in the treatment course. The standard approach was to complete the full 28-day course of steroids regardless of response, exposing non-responding patients to unnecessary immunosuppression and its attendant risks, including opportunistic infections, hyperglycemia, and gastrointestinal bleeding. The Lille Model changed this paradigm by providing a validated tool to assess steroid response at day 7, enabling clinicians to make an informed decision about whether to continue or discontinue corticosteroid therapy.

Components of the Lille Model

The Lille Model incorporates six variables, each reflecting a distinct aspect of hepatic function, systemic health, or treatment response.

Age (years): Older patients generally have diminished hepatic regenerative capacity, more accumulated liver damage, and a higher burden of comorbidities. In the formula, increasing age contributes negatively to the R value, resulting in a higher (worse) Lille score.

Serum Albumin at Baseline (g/L or g/dL): Albumin is a key indicator of hepatic synthetic function. The liver produces approximately 10 to 15 grams of albumin daily under normal conditions. In severe AH, albumin levels are often depressed. Higher albumin at baseline is favorable and lowers the Lille score.

Serum Bilirubin at Day 0 (umol/L or mg/dL): Bilirubin reflects the liver’s ability to conjugate and excrete this breakdown product of hemoglobin. Markedly elevated bilirubin at baseline indicates severe cholestasis and hepatocyte dysfunction, worsening prognosis.

Serum Bilirubin at Day 7 (umol/L or mg/dL): The change in bilirubin from day 0 to day 7 is the most critical dynamic variable. It captures the early treatment response to corticosteroids. A decrease suggests the inflammatory cascade is being controlled. The formula uses (Day 0 minus Day 7) so that a positive change (decreasing bilirubin) is favorable.

Serum Creatinine (mg/dL or umol/L): The Lille Model uses a binary variable for renal insufficiency: creatinine at or above 1.3 mg/dL (115 umol/L) is coded as 1, and below this threshold is coded as 0. Renal impairment may indicate hepatorenal syndrome, volume depletion, or concurrent acute kidney injury.

Prothrombin Time (seconds): PT measures the extrinsic pathway of coagulation and is highly sensitive to hepatic synthetic function. Prolonged PT indicates severely compromised hepatic synthesis and increases the Lille score.

How to Calculate the Lille Score: Step-by-Step

Calculating the Lille score requires collecting specific laboratory values at two time points. At baseline (day 0), before initiating corticosteroid therapy, record the patient’s age, serum albumin, total bilirubin, serum creatinine, and prothrombin time. After 7 days of corticosteroid treatment, measure serum bilirubin again.

First, determine the renal insufficiency variable: if serum creatinine is 1.3 mg/dL (115 umol/L) or higher, assign 1; otherwise assign 0. Second, calculate the change in bilirubin by subtracting the day 7 value from the day 0 value. Third, substitute all values into the linear predictor equation to compute R. Finally, apply the logistic transformation: Lille Score = exp(-R) / (1 + exp(-R)).

Interpreting the Lille Score

The Lille score is interpreted using a primary cutoff of 0.45. Patients with a score below 0.45 are classified as steroid responders with approximately 85 percent 6-month survival. Patients with a score of 0.45 or above are classified as non-responders with approximately 25 percent 6-month survival, and the recommendation is to discontinue corticosteroids.

A subsequent study by Louvet and colleagues in 2015 proposed a more refined three-tier classification: scores below 0.16 indicate complete responders with excellent prognosis, scores between 0.16 and 0.56 indicate partial responders with intermediate prognosis, and scores above 0.56 indicate null responders with very poor prognosis. This approach provides additional clinical nuance for transplant referral discussions.

Validation and Predictive Performance

The Lille Model has been extensively validated. In the derivation cohort of 320 patients, the AUROC was 0.89. In the validation cohort of 118 patients, the AUROC was 0.85. These values significantly outperformed Child-Pugh (AUROC 0.62), Maddrey DF (0.66), MELD (0.72), and Glasgow AH Score (0.67). Independent validation studies across different populations have confirmed robust predictive performance. Combining the MELD score with the Lille score provided the best predictive model for 2-month mortality with an AUROC of 0.90.

Day 4 Lille Score: An Earlier Assessment Option

Research has explored whether assessment at day 4 could provide similarly reliable prognostic information. Studies have demonstrated comparable predictive performance to the day 7 score. The rationale is compelling: every additional day of corticosteroid therapy in non-responding patients increases infection risk without benefit. However, the day 7 assessment remains the standard in most guidelines as it has a larger evidence base.

Relationship with Other Hepatic Scoring Systems

The Maddrey Discriminant Function (MDF) is typically the first score calculated to determine whether a patient has severe AH requiring steroids (MDF greater than 32). The Lille score is then calculated at day 7 to assess response.

The MELD score has become a widely used prognostic tool in AH. A MELD above 20 indicates severe AH. Combining MELD with the Lille score improves prognostic accuracy beyond either alone.

The Glasgow Alcoholic Hepatitis Score (GAHS) uses age, white blood cell count, urea, PT ratio, and bilirubin. The ABIC score (Age, Bilirubin, INR, Creatinine) stratifies patients into low, intermediate, and high-risk groups.

Clinical Application and Treatment Algorithm

In current clinical practice, the Lille Model is integrated into a stepwise treatment algorithm for severe AH. The pathway begins with identifying patients with suspected AH based on clinical presentation, including recent onset of jaundice in the setting of heavy alcohol use. Severity is assessed using MDF (greater than 32) or MELD (20 or above). Patients with severe AH who do not have contraindications to steroids are started on prednisolone 40 mg daily.

At day 7, the Lille score is calculated. If below 0.45, prednisolone is continued for 28 days followed by a taper. If 0.45 or above, steroids are discontinued and the clinical team considers alternative strategies including supportive care, early liver transplantation evaluation, or clinical trials. Alcohol abstinence remains the single most important factor influencing long-term outcomes regardless of Lille score.

Limitations of the Lille Model

While powerful, the Lille Model has several limitations. It was developed in predominantly Caucasian European populations, raising generalizability questions. It relies on accurate laboratory measurements at precisely timed intervals. The binary coding of renal insufficiency may miss patients with borderline creatinine values. The model does not account for portal hypertension, hepatic encephalopathy grade, nutritional status, or ongoing alcohol use.

Additionally, the model was designed for biopsy-proven severe AH treated with corticosteroids. Its applicability to patients who did not receive steroids, those treated with alternative therapies, or those diagnosed clinically (without biopsy) is less established. The model’s specificity for predicting steroid futility has been questioned, as some non-responders may still derive partial benefit.

Global Application and Population Considerations

The Lille Model has been applied across multiple continents. While originally developed in a French population, validation studies have been conducted in North America, Europe, Asia, and other regions. The model’s components are universally available, making it applicable in both resource-rich and resource-limited settings.

Different ethnic populations may have varying baseline laboratory values and susceptibilities to alcohol-related liver injury. Certain genetic polymorphisms in alcohol-metabolizing enzymes (ADH and ALDH variants) are more prevalent in East Asian populations. South Asian populations may present with AH at lower alcohol consumption levels. International guidelines from the AASLD, EASL, and ACG all reference the Lille Model as a recommended tool for assessing steroid response.

Emerging Research and Future Directions

Several areas of active research may influence how the model is used. Biomarker research is identifying novel predictors including IL-8, IL-6, TNF-alpha, hepatocyte growth factor, and alpha-fetoprotein. Early liver transplantation for selected steroid non-responders has created a new role for the Lille score as a gatekeeping tool. The STOPAH trial (2015, New England Journal of Medicine) confirmed the importance of early response assessment. Research into non-invasive biomarkers and imaging techniques may also influence future application.

Practical Considerations for Using This Calculator

Ensure all input values are in the correct units. The calculator supports both SI and conventional units with automatic conversion. Albumin can be entered in g/dL or g/L. Bilirubin values can be entered in mg/dL or umol/L. Creatinine can be entered in mg/dL or umol/L. Prothrombin time should be in seconds. Always use baseline (pre-treatment) values for albumin, bilirubin day 0, creatinine, and PT.

Unit Conversion Reference for Global Users

For albumin, multiply g/dL by 10 to convert to g/L. Normal albumin is approximately 3.5 to 5.0 g/dL (35 to 50 g/L). For total bilirubin, multiply mg/dL by 17.1 to convert to umol/L. Normal is approximately 0.1 to 1.2 mg/dL (1.7 to 20.5 umol/L). For creatinine, multiply mg/dL by 88.4 to convert to umol/L. The renal insufficiency threshold of 1.3 mg/dL corresponds to 115 umol/L.

Prothrombin time does not require conversion but some laboratories report only INR. The Lille Model requires PT in seconds. If only INR is available, PT can be estimated: PT (seconds) = INR x Mean Normal PT (typically 11 to 13.5 seconds). Direct PT measurement is preferred.

Combining Scoring Systems for Improved Prognostication

Combining multiple scoring systems improves accuracy. Louvet and colleagues demonstrated that the combination of MELD at baseline with Lille at day 7 was the most accurate model for predicting 2-month mortality. Some centers use a combined approach where patients with high MELD (above 30) and high Lille (above 0.56) are prioritized for early transplant evaluation.

Nutritional Support and Supportive Care

All patients with severe AH require comprehensive supportive care regardless of Lille score. Nutritional support is a cornerstone: 35 to 40 kcal/kg/day with 1.2 to 1.5 g/kg/day protein. Enteral nutrition is preferred. Additional care includes hepatic encephalopathy prophylaxis, ascites management, infection surveillance, and gastrointestinal bleeding prevention. Alcohol cessation counseling should begin during hospitalization and continue after discharge.

Frequently Asked Questions

Conclusion

The Lille Model remains one of the most important clinical tools in the management of severe alcohol-associated hepatitis. By integrating baseline clinical variables with a dynamic measure of treatment response, it provides clinicians with a robust, validated score to guide one of the most critical decisions in AH management: whether to continue or discontinue corticosteroid therapy. With its AUROC of 0.85 to 0.89 and clear clinical cutoff of 0.45, the Lille Model significantly outperforms other prognostic tools for this specific purpose. Its integration into clinical practice has enabled earlier identification of steroid non-responders, reduced unnecessary exposure to immunosuppressive therapy, and facilitated timely referral for liver transplantation. As research continues to develop novel therapies, the Lille Model will likely remain central to the clinical management algorithm for this devastating condition.